{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T09:49:05Z","timestamp":1792316945990,"version":"4.4.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"45","license":[{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute of Health Research","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.1016\/j.vaccine.2017.09.028","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T10:01:08Z","timestamp":1505988068000},"page":"6208-6217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":37,"title":["Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M\u2122"],"prefix":"10.1016","volume":"35","author":[{"given":"Navin","family":"Venkatraman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Anagnostou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carly","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgina","family":"Bowyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danny","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"L\u00f6vgren-Bengtsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Roberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Poulton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Lawrie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katie","family":"Ewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"V. S. Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2017.09.028_b0005","unstructured":"WHO, World Malaria Report; 2013."},{"key":"10.1016\/j.vaccine.2017.09.028_b0010","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 2014;11(7): e1001685.","DOI":"10.1371\/journal.pmed.1001685"},{"key":"10.1016\/j.vaccine.2017.09.028_b0015","doi-asserted-by":"crossref","unstructured":"Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet 2015;386(9988): 31\u201345.","DOI":"10.1016\/S0140-6736(15)60721-8"},{"issue":"24","key":"10.1016\/j.vaccine.2017.09.028_b0020","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1056\/NEJMoa1208394","article-title":"A phase 3 trial of RTS, S\/AS01 malaria vaccine in African infants","volume":"367","author":"RTS, S Clinical Trials Partnership","year":"2012","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.vaccine.2017.09.028_b0025","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1056\/NEJMoa1102287","article-title":"First results of phase 3 trial of RTS, S\/AS01 malaria vaccine in African children","volume":"365","author":"Agnandji","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.vaccine.2017.09.028_b0030","unstructured":"Malaria Vaccine Funders Group. Malaria Vaccine Technology Roadmap; 2013 [20\/3\/13]; Available from: http:\/\/www.who.int\/immunization\/topics\/malaria\/vaccine_roadmap\/TRM_update_nov13.pdf?ua=1."},{"issue":"3","key":"10.1016\/j.vaccine.2017.09.028_b0035","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.4049\/jimmunol.165.3.1453","article-title":"The complexity of protective immunity against liver-stage malaria","volume":"165","author":"Doolan","year":"2000","journal-title":"J Immunol"},{"issue":"7","key":"10.1016\/j.vaccine.2017.09.028_b0040","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1128\/IAI.62.7.2979-2983.1994","article-title":"Complete protection against Plasmodium yoelii by adoptive transfer of a CD8+ cytotoxic T-cell clone recognizing sporozoite surface protein 2","volume":"62","author":"Khusmith","year":"1994","journal-title":"Infect Immun"},{"issue":"6240","key":"10.1016\/j.vaccine.2017.09.028_b0045","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/341323a0","article-title":"Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria","volume":"341","author":"Romero","year":"1989","journal-title":"Nature"},{"issue":"4","key":"10.1016\/j.vaccine.2017.09.028_b0050","doi-asserted-by":"crossref","first-page":"e2027","DOI":"10.1371\/journal.pone.0002027","article-title":"Correlation of memory T cell responses against TRAP with protection from clinical malaria, and CD4 CD25 high T cells with susceptibility in Kenyans","volume":"3","author":"Todryk","year":"2008","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2017.09.028_b0055","doi-asserted-by":"crossref","first-page":"3300","DOI":"10.1073\/pnas.88.8.3300","article-title":"Human cytotoxic T lymphocytes against the Plasmodium falciparum circumsporozoite protein","volume":"88","author":"Malik","year":"1991","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.vaccine.2017.09.028_b0060","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1038\/ncomms3836","article-title":"Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation","volume":"4","author":"Ewer","year":"2013","journal-title":"Nat Commun"},{"issue":"286","key":"10.1016\/j.vaccine.2017.09.028_b0065","doi-asserted-by":"crossref","first-page":"286re5","DOI":"10.1126\/scitranslmed.aaa2373","article-title":"Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults","volume":"7","author":"Ogwang","year":"2015","journal-title":"Sci Transl Med"},{"issue":"5","key":"10.1016\/j.vaccine.2017.09.028_b0070","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jir850","article-title":"Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector","volume":"205","author":"O'Hara","year":"2012","journal-title":"J Infect Dis"},{"issue":"8","key":"10.1016\/j.vaccine.2017.09.028_b0075","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1038\/mt.2016.83","article-title":"Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African children and Infants","volume":"24","author":"Afolabi","year":"2016","journal-title":"Mol Ther"},{"issue":"2","key":"10.1016\/j.vaccine.2017.09.028_b0080","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ymthe.2016.11.003","article-title":"Viral vector malaria vaccines induce high-level T Cell and antibody responses in West African children and infants","volume":"25","author":"Bliss","year":"2017","journal-title":"Mol Ther"},{"issue":"11","key":"10.1016\/j.vaccine.2017.09.028_b0085","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1038\/mt.2014.109","article-title":"Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations","volume":"22","author":"Kimani","year":"2014","journal-title":"Mol Ther"},{"issue":"3","key":"10.1016\/j.vaccine.2017.09.028_b0090","doi-asserted-by":"crossref","first-page":"e57726","DOI":"10.1371\/journal.pone.0057726","article-title":"Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults","volume":"8","author":"Ogwang","year":"2013","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.vaccine.2017.09.028_b0095","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1093\/infdis\/jiu579","article-title":"Evaluation of the efficacy of ChAd63-MVA vectored vaccines expressing circumsporozoite protein and ME-TRAP against controlled human malaria infection in malaria-naive individuals","volume":"211","author":"Hodgson","year":"2015","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2017.09.028_b0100","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.mib.2016.04.006","article-title":"Malaria vaccines and human immune responses","volume":"32","author":"Long","year":"2016","journal-title":"Curr Opin Microbiol"},{"issue":"5","key":"10.1016\/j.vaccine.2017.09.028_b0105","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1093\/infdis\/jiw244","article-title":"Safety and high level efficacy of the combination malaria vaccine REGIMEN of RTS, S\/AS01B with Chimpanzee adenovirus 63 and modified vaccinia ankara vectored vaccines expressing ME-TRAP","volume":"214","author":"Rampling","year":"2016","journal-title":"J Infect Dis"},{"issue":"5","key":"10.1016\/j.vaccine.2017.09.028_b0110","doi-asserted-by":"crossref","first-page":"e0154757","DOI":"10.1371\/journal.pone.0154757","article-title":"Meta-analysis on randomized controlled trials of vaccines with QS-21 or ISCOMATRIX adjuvant: safety and tolerability","volume":"11","author":"Bigaeva","year":"2016","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.vaccine.2017.09.028_b0115","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1586\/14760584.2013.814822","article-title":"Matrix-M adjuvant: enhancing immune responses by \u2018setting the stage\u2019 for the antigen","volume":"12","author":"Bengtsson","year":"2013","journal-title":"Expert Rev Vaccines"},{"issue":"45","key":"10.1016\/j.vaccine.2017.09.028_b0120","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1016\/j.vaccine.2011.08.042","article-title":"Evaluation of a virosomal H5N1 vaccine formulated with Matrix M adjuvant in a phase I clinical trial","volume":"29","author":"Cox","year":"2011","journal-title":"Vaccine"},{"issue":"7","key":"10.1016\/j.vaccine.2017.09.028_b0125","doi-asserted-by":"crossref","first-page":"e0131652","DOI":"10.1371\/journal.pone.0131652","article-title":"Matrix M H5N1 vaccine induces cross-h5 clade humoral immune responses in a randomized clinical trial and provides protection from highly pathogenic influenza challenge in Ferrets","volume":"10","author":"Cox","year":"2015","journal-title":"PLoS One"},{"issue":"16","key":"10.1016\/j.vaccine.2017.09.028_b0130","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1016\/j.vaccine.2016.02.033","article-title":"Matrix-M adjuvant enhances antibody, cellular and protective immune responses of a Zaire Ebola\/Makona virus glycoprotein (GP) nanoparticle vaccine in mice","volume":"34","author":"Bengtsson","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2017.09.028_b0135","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12985-015-0435-9","article-title":"Matrix-M adjuvation broadens protection induced by seasonal trivalent virosomal influenza vaccine","volume":"12","author":"Cox","year":"2015","journal-title":"Virol J"},{"issue":"6","key":"10.1016\/j.vaccine.2017.09.028_b0140","doi-asserted-by":"crossref","first-page":"e29","DOI":"10.1371\/journal.pctr.0010029","article-title":"A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya","volume":"1","author":"Bejon","year":"2006","journal-title":"PLoS Clin Trials"},{"issue":"1","key":"10.1016\/j.vaccine.2017.09.028_b0145","doi-asserted-by":"crossref","first-page":"6","DOI":"10.12665\/J141.Hahn","article-title":"Rapid manufacture and release of a GMP batch of Zaire ebolavirus glycoprotein vaccine made using recombinant baculovirus-Sf9 insect cell culture technology","volume":"14","author":"Hahn","year":"2015","journal-title":"BioProcess J"},{"issue":"2","key":"10.1016\/j.vaccine.2017.09.028_b0150","doi-asserted-by":"crossref","first-page":"e31208","DOI":"10.1371\/journal.pone.0031208","article-title":"Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors","volume":"7","author":"Sheehy","year":"2012","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2017.09.028_b0155","doi-asserted-by":"crossref","first-page":"e115161","DOI":"10.1371\/journal.pone.0115161","article-title":"A phase Ia study to assess the safety and immunogenicity of new malaria vaccine candidates ChAd63 CS administered alone and with MVA CS","volume":"9","author":"de Barra","year":"2014","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.vaccine.2017.09.028_b0160","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/mt.2011.176","article-title":"Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors","volume":"19","author":"Sheehy","year":"2011","journal-title":"Mol Ther"},{"issue":"5","key":"10.1016\/j.vaccine.2017.09.028_b0165","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1086\/315074","article-title":"Potent induction of focused Th1-type cellular and humoral immune responses by RTS, S\/SBAS2, a recombinant Plasmodium falciparum malaria vaccine","volume":"180","author":"Lalvani","year":"1999","journal-title":"J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312483?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X17312483?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T01:58:14Z","timestamp":1602986294000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X17312483"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10]]},"references-count":33,"journal-issue":{"issue":"45","published-print":{"date-parts":[[2017,10]]}},"alternative-id":["S0264410X17312483"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.028","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2017,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of heterologous prime-boost immunization with viral-vectored malaria vaccines adjuvanted with Matrix-M\u2122","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}